https://www.healthday.com/healthpro-news/neurology/fremanezumab-reduces-number-of-migraine-days-in-children-teens
Fremanezumab yields a greater reduction in the number of migraine days and headache days than placebo among children and adolescents with episodic migraine.
fremanezumabreducesnumbermigrainedays
https://pubmed.ncbi.nlm.nih.gov/36949388/
Fremanezumab is characterized by an early and sustained efficacy in HFEM and CM patients with multiple preventive treatment failures in real-life, revealing an...
earlysustainedefficacyfremanezumabweeks